Overall Status

Completed (1)

Not yet recruiting (1)

Recruiting (1)

Phase

phase 2 (2)

n/a (1)

Sponsor

National Cancer Institute (NCI) (2)

Shanghai Jiao Tong University School of Medicine (1)

Collaborator

Intervention

biospecimen collection (1)

doxorubicin, vincristine, and etoposide with mitotane (1)

individualized mrna neoantigen vaccine (mrna-0523-l001) (1)

ipilimumab (1)

nivolumab (1)

Study Documents

Intervention Type

biological (2)

drug (1)

procedure (1)

Funder Type

NIH (2)

Other (1)

Study Type

Interventional (3)

adrenal cortical carcinoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma Trial in Shanghai (individualized mRNA

Not yet recruiting

Adrenal Cortical Carcinoma
+3 more

individualized mRNA neoantigen vaccine (mRNA-0523-L001)

Shanghai, Shanghai, China

Ruijin hospital, Shanghai Jiao-Tong University School of Medicin

Nov 19, 2023

Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma Trial in Guam, United States (Biospecimen

Recruiting

Acinar Cell Carcinoma
+93 more

Biospecimen Collection
+2 more

Birmingham, Alabama
+998 more

Aug 23, 2022

Adrenal Cortical Carcinoma Trial run by the NCI (doxorubicin, vincristine, and etoposide with mitotane)

Completed

Adrenal Cortical Carcinoma

doxorubicin, vincristine, and etoposide with mitotane

Bethesda, Maryland

National Cancer Institute (NCI)

Mar 3, 2008